Inovio Pharmaceuticals, Inc.
NASDAQ:INOBiotechnology
Healthcare
$1.71 -0.90%
-$0.01 today
- Market cap
- $118.15M
- Beta
- 1.49
- P/E (TTM)
- -8.9
- EPS (TTM)
- -$0.12
52W Low $1.03High $2.98
Volume 9.92M
Average 2.73M
Balance Sheet
Inspect the capital base behind the business.
Assets
$74.31M
FY 2025 · Annual
-34.4% YoYLiabilities
$50.21M
FY 2025 · Annual
+12.4% YoYEquity
$24.10M
FY 2025 · Annual
-64.8% YoYBalance Sheet
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 71.14M | 46.33M | 14.31M | 65.81M | 44.27M |
| Short-term Investments | 330.17M | 206.67M | 130.98M | 28.3M | 14.24M |
| Net Receivables | 8.03M | 11.74M | 2.41M | 1.2M | 450 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 261.19K | 30.38M | 20.43K | 0 | 0 |
| Total Current Assets | 448.44M | 315.24M | 153.11M | 97.83M | 61.12M |
| Property, Plant & Equipment (Net) | 29.02M | 17.96M | 14.45M | 11.77M | 9.07M |
| Goodwill | 10.51M | 10.51M | 0 | 0 | 0 |
| Intangible Assets | 2.63M | 2.13M | 0 | 0 | 0 |
| Long-term Investments | 3.91M | 2.01M | 2.78M | 1.61M | 2.1M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.43M | 684.04K | 605.32K | 1.98M | 2.01M |
| Total Non-current Assets | 47.5M | 33.29M | 17.84M | 15.37M | 13.19M |
| Total Assets | 495.94M | 348.53M | 170.95M | 113.2M | 74.31M |
| Account Payables | 27.97M | 21.08M | 4.65M | 6.44M | 2.62M |
| Short-term Debt | 0 | 0 | 16.77M | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 21.63K | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 20.71M | 15.14M | 9.95M | 23.26M | 36.44M |
| Total Current Liabilities | 65.74M | 96.87M | 42.57M | 35.33M | 43.67M |
| Long-term Debt | 14.96M | 16.61M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 32.05K | 32.05K | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 64.36K | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 14.83K | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 30.53M | 29.3M | 11.03M | 9.37M | 6.55M |
| Total Liabilities | 96.27M | 126.17M | 53.6M | 44.69M | 50.21M |
| Common Stock | 217.38K | 21.09K | 22.79K | 36.1K | 69K |
| Retained Earnings | (1.21B) | (1.49B) | (1.62B) | (1.73B) | (1.82B) |
| Accumulated OCI | (282.24K) | (698.74K) | (662.6K) | (675.67K) | (637.96K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 399.67M | 222.36M | 117.35M | 68.5M | 24.1M |
| Total Debt | 33.02M | 32.07M | 30.21M | 11.87M | 9.37M |
| Net Debt | (38.12M) | (14.25M) | 15.9M | (53.95M) | (34.91M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $26.3M |
| Short-term Investments | $11.4M |
| Other Current | $1.8M |
| Total Current Assets | $39.4M |
| PP&E (Net) | $8.3M |
| Other Non-current | $2.0M |
| Total Non-current Assets | $10.3M |
| Total Assets | $49.8M |
Analysis
Selected assets total $49.8M for Latest. The largest visible component is Cash & Equivalents at $26.3M, about 52.8% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| FWP | FWP filing | Nov 6, 2026 | |
| 424B5 | 424B5 filing | Nov 6, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 5, 2026 | |
| 424B5 | 424B5 filing | Nov 5, 2026 |
How much cash does INO have?
Inovio Pharmaceuticals, Inc. (INO) reported $44.27M in cash and equivalents in fiscal 2025.
How much debt does INO carry?
Inovio Pharmaceuticals, Inc. (INO) reported $9.37M of total debt, with net debt of -$34.91M.
Continue the stock analysis
Jump to another research area for this company.